Abstract
GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Current Drug Delivery
Title:Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Volume: 15 Issue: 5
Author(s): Rawda Y. AlSheyyab*, Bashar M. Al-Taani, Rana M. Obeidat, Motasem M. Alsmadi, Rafeef K. Masaedeh and Raghda N. Sabat
Affiliation:
- Jordan University of Science and Technology, Pharmaceutical Technology, Irbid, Jordan,Jordan
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Abstract: GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Export Options
About this article
Cite this article as:
AlSheyyab Y. Rawda *, Al-Taani M. Bashar , Obeidat M. Rana , Alsmadi M. Motasem , Masaedeh K. Rafeef and Sabat N. Raghda , Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists, Current Drug Delivery 2018; 15 (5) . https://dx.doi.org/10.2174/1567201815666180214142300
DOI https://dx.doi.org/10.2174/1567201815666180214142300 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
Current Drug Metabolism Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Cytotoxic Potential of Phenothiazines
Current Drug Targets Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine CD164 as a Basophil Activation Marker
Current Pharmaceutical Design A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines
Letters in Organic Chemistry Editorial (Hot Topic: Pharmacological and Molecular Targets in Cellular Redox Status Maintenance)
Current Pharmaceutical Design Analysis of the Essential Oils of Five Artemisia Species and Evaluation of their Cytotoxic and Proapoptotic Effects
Mini-Reviews in Medicinal Chemistry The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Leflunomide, a Reversible Monoamine Oxidase Inhibitor
Central Nervous System Agents in Medicinal Chemistry Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening